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Available online xxxxPost-exercise cardiac troponin (cTn) elevation is a recognised phenomenonwhich historically has been detected
using standard sensitivity assays. More recently high-sensitivity assays have been developed and are now the
gold standard for detection of cTn in the clinical setting. Although the assay's enhanced sensitivity confers bene-
ﬁts it has created new challenges for clinicians. By evaluating the change in cTn values over time, taking into ac-
count biological and analytical variation, the clinician is able to differentiate between a pathological and normal
cTn value. As a result, serial cTn testing has become a fundamental component of the clinical assessment of chest
pain patients and is included in the most recent deﬁnition for myocardial infarction and the latest guidelines for
the management of acute coronary syndromes without persistent ST-segment elevation. A review of the cTn ki-
netics literature demonstrates a pattern of elevation and peak within the ﬁrst 4 h after exercise dropping within
24 h. In contrast myocardial necrosis demonstrates a later cTn peakwith a slower downslope occurring over sev-
eral days. Understanding cTn kinetics facilitates clinician's decisionmakingwhen presentedwith a chest pain pa-
tient post-exercise. Furthermore, it helps elucidate the underlying mechanism and establish the clinical
signiﬁcance of post-exercise cTn elevation, which in all other situations confers negative prognostic value. We
recommend serial cTn testing in this scenario with a suggested algorithm included in this review.
© 2019 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Troponin
Kinetics
Heart
Exercise1. Introduction
It is well accepted that short bouts of moderate intensity exercise
taken regularly are beneﬁcial for health [1,2].What is unclear iswhether
this still applies to those participating in strenuous and/or prolonged ex-
ercise. Some of this uncertainty has arisen from the growing literature
demonstrating a rise in the cardiac biomarker, troponin (cTn), following
endurance exercise. Understanding the signiﬁcance of this is important.
Firstly, to enable clinicians to give informed advice to those wishing to
participate in such exercise and secondly to facilitate the interpretation
of troponin levels in the context of an endurance event.ability and freedom from bias of
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sculature, https://doi.org/10.12. cTn testing in the clinical setting
Due to their ability to detect cTn much earlier, high-sensitivity cTn
(HS-cTn) assays have largely replaced those of standard sensitivity in
the clinical setting [3–5]. The enhanced sensitivity of these newer assays
has led to the detection of cTn in healthy individuals [6] which in con-
junction with the existence of biological and analytical variability [7,8]
has made it harder to differentiate between a pathological and normal
cTn value. To overcome this serial blood testing and the evaluation of
troponin kinetics has become a fundamental component of the clinical
assessment of chest pain patients.
The change criteria for a pathological rise between the twoblood sam-
pling points is assay speciﬁc and depends on a variety of factors including
the timing of baseline sampling and the onset of symptoms. The key is
that any change detected is greater than the combined biological and an-
alytical variation. A 20% or greater change from an elevated cTn value is
set as the threshold for diagnosis of myocardial necrosis [9,10] and repre-
sents a signiﬁcant N3 standard deviations of variation associated with an
elevated baseline concentration change in cTn on the basis of a 5–7% an-
alytical total CV [10]. For clinical situations where the baseline sampling
value is below the URL a change in the range of 50–60% is needed [11].
This is not error proof and thus it is recommended [12] that if the clinical-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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tional sampling is performed.
The fourth deﬁnition of myocardial infarction includes serial testing
as a criterion for its diagnosis [13]. However, it deﬁnes this detection of a
rise and/or fall of cTn with at least 1 value above the 99th percentile
upper reference limit (URL) as acute myocardial injury (MIn) and ex-
plains that this may exist as a clinical entity in its own right. In addition,
this latest consensus statement updates the deﬁnitions of the ﬁve sub-
types of MI. Criteria required for the diagnosis of types 1, 2 and 3 in-
cludes acute MIn in conjunction with clinical evidence of myocardial
ischaemia. The different subtypes are then differentiated by the
aetiology of the myocardial ischaemia. MI caused by atherothrombotic
coronary artery disease (CAD) and usually precipitated by atheroscle-
rotic plaque disruption (rupture or erosion) is designated as type 1 MI.
Evidence of an imbalance between myocardial oxygen supply and de-
mand unrelated to acute atherothrombosis meets the criteria for type
2MI. Cardiac death in patients with symptoms suggestive ofmyocardial
ischaemia and presumed new ischaemic ECG changes before cTn values
become available or abnormal meets criteria for type 3 MI.
The 2015 ESC guidelines for themanagement of acute coronary syn-
dromes (ACS) in patients presenting without persistent ST-segment el-
evation [12] continues to recommend serial cTn testing and presents a
0 h/3 h and 0 h/1 h rule in and rule out algorithm for clinical use.
Those patients presenting post-exercise typically fall within this cohort
and thus utilisation of their suggested cTn testing schedule is logical.
3. cTn elevation following exercise
Earlier investigations using 2nd and 3rd generation assays reported
signiﬁcant elevations of cTnT and I following endurance exercise
[14–18]. Deriving common ﬁndings from these studies has been chal-
lenging for several reasons. Variables, including exercise modality, in-
tensity and duration of exercise, are not standardised between studies.
Furthermore, the use of different assays, each with its own sensitivity
and speciﬁcity and threshold levels for detection and limit, makes
cross comparison of results difﬁcult. Finally, the timing for sampling tro-
ponin can differ between trials. As described later, the levels of troponin
rise and fall over 24 h making it imperative to standardise sampling
time points.
By taking advantage of the existence of only one cTnT assay (second
or third- generation) (Roche Diagnostics, Lewes, UK) and limiting the
search criteria to cTnT, Shave and colleagues were able to combine
data sets and overcome some of these limitations. The authors exam-
ined 1120 cases from 26 trials ﬁnding that post-exercise cTnT concen-
trations exceeded the assay's lower limit in approximately one-half of
participants. In addition, that the detection of cTnT following cycling
races was found to be approximately half of that found after running
events. The incidence of a cTnT rise was found to increase the shorter
the duration of the endurance event and the lower the body mass of
the participant. Regwan et al. performed a systematic review of 16 stud-
ies investigating cTn elevation related to marathon running and in-
cluded the detection of TnT and I by different standard sensitivity
assays. In order to pool data, levels of cTnT and I were categorised ac-
cording to whether they were detectable (non-negative) or above the
threshold for myocardial necrosis (above the URL). 6/940 (0.6%) of sub-
jects were reported to have a non-negative cTn prior to the race, com-
pared to 579/936 (62%) after the race (P b 0.001). When the threshold
criteria for myocardial necrosis was used, the pre-race incidence of pos-
itivity was 0/848 (0%) and post-race was 124/845 (15%).
More recently the number of studies using HS- cTn assays has in-
creased. A systematic review performed by Vilela et al. investigates
HS-cTn elevation after running [19]. Ten studies with a total number
of 479 runners between 2009 and 2013 are identiﬁed. Although again
not directly comparable due to the use of different assays the authors at-
tempt to pool results by dichotomising data into those with values
above and below the 99th percentile of the HS-cTn assay used. TheyPlease cite this article as: P. Baker, T. Leckie, D. Harrington, et al., Exerc
mechanism and implications, IJC Heart & Vasculature, https://doi.org/10.1ﬁnd that all participants demonstrated a detectable HS-cTn following
completion of the race and that 69.8% (296/424) had a value above
the 99th percentile, the cut-off used for myocardial necrosis. More re-
cently Richardson et al. [20] evaluate HS-cTn using a ﬁfth generation
high-sensitivity assay (Elecsys, Roche Modular E170) and ﬁnd that all
52 marathon runners have an increase above the reference value,
reporting mean post-race values of 74 ± 30 ng/L−. These studies do
not differentiate between those elevated troponin levels of male and fe-
male participants. Although differences between the threshold set for
the 99th percentile has been seen [21,22], evidence suggests that a
change to differentiate between gender is not needed for diagnostic
performance [23].
Enhanced sensitivity of assays has increased the number of detect-
able cTn values, including those above the level used to diagnose myo-
cardial necrosis. Taking into account the central role troponin plays in
the risk stratiﬁcation of ACS it is imperative that the mechanism and
thus signiﬁcance of troponin rise is understood.4. Mechanism of cTn release
Several theories have been proposed to explain the mechanism un-
derlying Tn release following exercise. Currently themost well received
is that of increased membrane permeability of cardiomyocytes,
whereby unbound cTn found in the cytosol diffuses across a concentra-
tion gradient from the intra- to extra-cellular compartment. The initial
peak, illustrated in Fig. 2, would represent this release of Tn through
the sacrolemmal membrane with levels subsequently decreasing over
24 h reﬂecting the half-life and clearance of cTn subunits thereafter.
It has been suggested that mechanical stress through the transient
disruption (wounding) of the sarcolemma might be responsible for
this increased membrane permeability. Initially demonstrated in the
skeletal muscle of rats after a period of downhill running [24], it was
shown that these ‘cell wounds’ resolve within 24 h following the same
time-course as the CK levels detected. These events have also beendem-
onstrated in-vivo cardiac muscle and have been associated with the re-
lease of growth factors [25,26]. It is logical to think, therefore, that
troponin elevation following exercise may be a reﬂection of the adap-
tive cellular cascades seen in exercise-induced cardiac remodelling
and hypertrophy.
An alternative hypothesis is that of integrin-stimulated troponin re-
lease. Integrins are transmembrane glycoproteins that mediate the at-
tachment of cells to the extracellular matrix [27]. They are responsive
to stretch, such as that seen in haemodynamic overload, and transmit
force across the plasma membrane. This has been shown to trigger in-
tracellular signalling pathways responsible for cardiac hypertrophy
[28] and it is proposed that Tn is released as a by-product of this process.
Recently, Hessel et al. [29] linked the stimulation of integrin to the re-
versible release of Tn from cultured cardiomyocytes. The pentapeptide
Gly-Arg-Gly-Asp-Ser is a known agonist for integrin stimulation. Treat-
ment of myocytes with this peptide resulted in a two to three-fold in-
crease in TnI release versus various controls. Reversible myocardial
injury was inferred by the absence of LDH release in treated cells rela-
tive to controls.
There is uncertainty as to how the intracellular cTn moves into the
bloodstream. An alternative mechanism of increased membrane per-
meability has been suggested. This involves the formation of blebs
which bud off from the plasma membrane of the cell, these have been
seen in the liver in response to cellular ischaemia [30]. If the ischaemia
is limited and re‑oxygenation occurs the blebs may be released into the
circulationwithout rupture of the plasmamembrane, resulting in a one-
off release of cytoplasmic contents. If the ischaemia is sustained the
blebs will grow and eventually rupture leading to cell necrosis. Support
for this process occurring in the heart comes from studies showing the
presence of blebs on cultured cardiomyocytes subjected to hypoxia
and release of cTn, without the development of cellular necrosis [31].ise-induced cardiac troponin elevation: An update on the evidence,
016/j.ijcha.2019.03.001
Table 1
Overview of trials showing cTn release kinetics.
Study (year) N Male/ female Mean age (years) Type of race Troponin Timing of sample collection
(bolded timepoint giving highest prevalence)
Highest prevalence of post-exercise
cTn elevation
Neumayr et al (2001) [15] 38 38/ 0 35 230km mountain cycle at
5500km altitude
TnI Baseline, immediately and
1 day after the race
13/38 (34%) above URL of 0.05ug/L
Hermann et al (2003) [46] 46 40/ 6 40 Marathon TnT
TnI
Baseline, b15 mins, 3 and 24 hours (9/46) after the race TnT – not documented
TnI – 33/46 (72%) above URL of 0.04ug/L and
27/46 (58%) above AMI cut off of 0.06ug/L
Frassl et al (2008) [42] 15 0/ 15 37 Marathon TnT
TnI
Baseline, immediately and 24 and 72 hours after the race TnT – 8/15 (53%) above URL/AMI cut off of
0.01ng/mL
TnI – 5/15 (33%) above URL of 0.03ug/mL
La Gerche et al (2008) [38] 27 20/ 7 32 Ultra endurance triathlon
(3.8km swim, 180km cycle,
42.2km run)
TnI Baseline, immediately and 1 week after the race 15/26 (58%) above URL of 0.16ug/L
Middleton et al (2008) [37] 9 9/ 0 - Treadmill marathon TnT Baseline and then every 30 mins within the race and 1,
3, 6, 12 and 24 hours after race completion
9/9 (100%) within race and 8/9 (89%) after race
completion, URL not documented
Serrano-Osteriz et al (2011) [47] 21 19/ 2 38 Treadmill running for 45, 90 &
180 mins at 85 and 90% IAT
TnI Baseline, within 30 mins and 3 hours after the race 0/19 (0%) above URL of 0.04ug/L
Scherr et al (2011) [41] 102 102/ 0 42 Marathon HS-TnT Baseline, within 1 hour, 24 and 72 hours after the race 91/102 (89%) above URL of 14ng/L
Nie et al (2011) [39] 12 12/ 0 adolescents 16 Track running TnT
TnI
Baseline, 2, 4 and 24 hours after the race TnT – 2/3 (67%) above threshold for MIn
0.03ng/mL and for MI 0.05ng/ml
TnI – 11/12 () above threshold for MIn
0.06ng/mL and ¼ (25%) for MI 0.5ng/mL
Tian et al (2012) [45] 26 13/ 0 (adults) and
13/ 0 (adolescents)
24 and 14
respectively
90 minutes treadmill running
at 90% VT
HS-TnT Baseline, immediately after and 1, 2, 3, 4, 5, 6, and 24
hours after the race
Adults – 11/13 (85%) above URL of 14ng/L
Adolescents - 12/13 (92%) above URL of 14ng/L
Wilhelm et al (2012) [44] 10 10/ 0 34.9 Marathon HS-TnT Baseline, immediately after and
1, 5 and 8 days after the race
9/10 (90%) above URL of 14ng/L
Roca (2017) [43] 79 57/ 22 39 Marathon HS-TnT Baseline, within 2 hours and
48 hours after the race
79/79 (100%) above URL of 14ng/L
Legaz-Arrese (2017) [40] 66 7/9 (adults) and
25/25 (adolescents)
31 and 15
respectively
Swimming HS-TnT Baseline, immediately after and 1, 3, 6, 12 and 24
hours after the race
41/66 (62%) above URL of 14ng/L
Baker et al (2019) unpublished 26 18/ 8 40 Marathon HS-TnT Baseline, immediately after and 3, 6 and 24 hours
after race
26/26 (100%) above URL of 14ng/L
BNP= brain natriuretic protein; TnI = cardiac troponin I; TnT= cardiac troponin T; CK= creatine kinase; h-FABP= heart-type fatty acid binding protein; HS-CRP = high-sensitivity C reactive protein; HS-TnT high-sensitivity troponin T;
HBD = hydroxybutyrate dehydrogenase; IL-6 = interleukin 6; NT-proBNP = N terminal pro-hormone of brain natriuretic peptide; N = number of runners.
This table illustrates all studies demonstrating cTn kinetics after exercise. It describes the basic demographics of the participants (age, sex), exercise performed and sampling points used.
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4 P. Baker et al. / IJC Heart & Vasculature xxx (xxxx) xxxWhether the release of cTn from themyocardium is related to intact
subunits or degradation products is also under debate. In contrast to
Hessel's study [29] where intact cTn is released, Feng and colleagues
[32] demonstrated the release of degraded cTn subunits in response to
preload. Without having assays speciﬁc to cTn degradation products,
the form of cTn released following exercise is not known.
Tn release following prolonged and/or strenuous exercise could be
secondary to subclinical apoptosis or necrosis. The kinetics of exercise-
induced cTn rise with a peak within the ﬁrst 1–4 h and falling levels
thereafter with resolution at 72 h make this suggestion unlikely. This
in contrast to the peak seen at 24 h after a type 1 MI peak with contin-
ued sustained levels for several days [33]. Finally injured skeletalmuscle
may release proteins that are detected by TnT assays resulting in situa-
tions where elevated cTn values may originate from skeletal muscle
[34–36]. This as yet has only been seen in those neuromuscular condi-
tions and its applicability to healthy participants completing a bout of
exercise is uncertain.5. Kinetics of cTn release
In order to understand the underlyingmechanism, it is useful to look
at the kinetics of cTn release following a bout of endurance exercise. A
review of the literature identiﬁes 12 studies investigating the kinetics
of cTn release following prolonged exercise [15,37–47] (see Table 1).
All cTn kinetic trials except that by Middleton et al. [37] demonstrate a
peak within the ﬁrst 24 h after exercise. To establish the timing of the
cTn peak blood samples must be drawn at multiple time points within
this time. The most comprehensive data set is provided by Tian et al.
[45] who conduct HS-cTnT sampling at 1, 2, 3, 4, 5, 6 and 24 h. They con-
ﬁrm a cTn peak at 3–4 h in 13 adolescents and 13 adults after 90min of
treadmill running at 90% of ventilatory threshold. However when eval-
uating cTn kinetic studies conducted following a marathon using the
gold standard HS-cTnT assay [41,43,44] sampling is only performed
from 24 h onwards and thus a comprehensive trend of the rise and
fall of troponin cannot be seen. To expand on our understanding of
cTn kinetics in the ﬁeld we evaluated runners at multiple time points
within the ﬁrst 24 h of marathon completion. We believe we are the
ﬁrst study to do this and thus are providing valuable new information
in this ﬁeld.Fig. 1. CTnT kinetics pre-marathon and 0, 3, 6 and 24 h post marathon. Mean (X) and standard
indicates reference value (99th percentile) of 14 ng/L−.
Please cite this article as: P. Baker, T. Leckie, D. Harrington, et al., Exerc
mechanism and implications, IJC Heart & Vasculature, https://doi.org/10.16. cTn kinetics data following 2017 Brighton Marathon
As part of a subgroup analysis looking at cTnT rise following comple-
tion of the 2017 Brighton Marathon, 28 runners consented to further
blood draws. Sampling timing included baseline, 0, 3, 6 and 24 h after
themarathon. The HS-cTnT assay used (RocheModular E170 (ﬁfth gen-
eration); Basel, Switzerland) had a lowest limit of detection (LLD) of
3 ng/L and diagnostic levels for myocardial necrosis, based on the 99th
percentile of the individual cTnT assay with a coefﬁcient of variation
≤10%, were 14 ng/L−. Baseline characteristics are given in Table 1.
All samples, including those taken before the race, were detectable
for troponin with the HS-cTn assay. Immediately following and 3 h
after the marathon troponin levels for all participants exceeded the
threshold for diagnosis of myocardial infarction. At 6 h this fell to 90%
and at 24 h to 22% of participants (Fig. 1).
When comparing our data to that seen in the study by Tian et al. sev-
eral differences are seen. Firstly, the timing of the cTn peak is earlier in our
study with a maximal cTn value occurring at 1 or 3 h, with the majority
occurring within the ﬁrst hour after the marathon (17/26). Furthermore,
datawithin Tian's study demonstrates reducedvariancewhichmaybe re-
lated to thematching of training status in participants and the exposure to
an exercise regime with a shorter ﬁxed duration and intensity. This is in
contrast to our study where runners would set their own running pace
and be exposed to additional environmental factors such as temperature.
The disparity between the timing of peak cTnT ismore likely to be related
duration rather exercise intensity. Richardson et al. [20] showed thatmar-
athon runners exercised at 101±5%of ventilatory threshold, theﬁndings
also demonstrated that working at a greater relative exercise intensity
was associated with greater cTn. This intensity is much greater than
that used by Tian et al. [45] or by Serrano-Ostariz et al. [47]who also dem-
onstrated peak values to occur earlier after lower intensity work. Data
showed working at 85% of the individual anaerobic threshold (IAT) in-
duced peak values 30 min post exercise in comparison to 3 h for 95% of
IAT. Therefore, the duration of exercise (265 ± 52 min in this study)
seems to be the most important comparative factor, allowing Tn levels
longer to rise before post-race measurement can occur.
Our data, and that of the studies found above, is at odds with the
study by Middleton et al. [37]. They investigated nine trained males
over the duration of a treadmill marathon. Although the data showed
a cTn rise during marathon running, cTn then returned to baselinedeviation of high-sensitivity cTnT values at baseline and 0, 3, 6 and 24 h. The dotted line
ise-induced cardiac troponin elevation: An update on the evidence,
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Fig. 2. Algorithm outlining proposed management of patients with suspected ACS after exercise Algorithm for the initiation of cTnT testing in patients with suspect non ST-elevation ACS
syndrome after exercise. This is proposed to supplement not replace standard clinical guidelines. High risk features include haemodynamic instability or shock, ongoing chest pain
refractory to medical treatment, heart failure, life threatening arrhythmias or arrest and dynamic ST or T wave changes.
5P. Baker et al. / IJC Heart & Vasculature xxx (xxxx) xxxbefore the end of activity. Additionally, participants demonstrated a bi-
phasic response with peak values returning 12–24 h post-race. This re-
sponse is difﬁcult to explain but could be as a result of participants
recovering and attempting to restart daily activity 12–24 h post mara-
thon. The lack of in-exercise blood sampling in the present study and
the literature base is a limitation and requires further investigation.
7. Clinical approach to patients with post-exercise troponin elevation
CTn testing continues to play a central role in the risk stratiﬁcation
and subsequent management of those with an acute coronary syn-
drome. Updated guidance on the diagnosis and management of MI
and Non ST-elevation ACS recommends the use of the 5th generation
HS- cTn assays [9,12]. Serial testing, of at least two sampling points, is
recommended to overcome the analytical and biological variation that
is associatedwith HS-cTn assays. Using our data, and that from other ki-
netics studies, we support the use of repeated samples to establish cTn
kineticswhen attempting to differentiate between cTn elevation related
to exercise and that of other causes. Using this approach in combination
with the latest ESC guidelines for the management of acute coronary
syndrome without persistent ST-elevation [12] allows the formulation
of the below algorithm (Fig. 2) which updates that proposed by Shave
et al. [48]. It is important to note that the ﬂow chart is no replacement
for clinical judgement and is meant to facilitate the clinical in their deci-
sion making process. We would urge, in the situation of clinical uncer-
tainty, that repeated cTn testing and further investigations including
evaluation by an experienced cardiologist occur in the hospital setting.
8. Further studies
Although a variety of plausible mechanisms for post-exercise cTn el-
evation have been proposed no one has been conﬁrmed. WithoutPlease cite this article as: P. Baker, T. Leckie, D. Harrington, et al., Exerc
mechanism and implications, IJC Heart & Vasculature, https://doi.org/10.1understanding the mechanism, elucidating the clinical signiﬁcance is
difﬁcult. With a large body of evidence indicating that cTn elevation in
other clinical situations has a quantitative negative prognosis the need
to establish this information has never been greater. Currently cTn ele-
vation following exercise is considered benign and affected individuals
are not counselled nor treated. Further investigations studying the
peak cTn value and/or the kinetics and its relation to future medical
events are warranted to ensure this line of action is appropriate.
9. Conclusion
CTn testing continues to be central to the assessment of patients
with a suspected ACS. The current use of HS-cTn assays reveals cTn ele-
vation in all those participating in exercise. In the short term these indi-
viduals show no increased risk of cardiac events however long term
data is lacking. Our ﬁndings and that from other studies suggest an
early cTn peak and that time frame therefore should be considered
when individuals present with elevated values following exercise. Tak-
ing into account the kinetics of post-exercise cTn elevation and the char-
acteristics of HS-cTn assays we propose a new updated clinical
algorithm for the management of those presenting with clinical symp-
toms compatible with a cardiac event after exercise.
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